Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy-Reference-Cited by-同舟云学术

Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy

Published:2019-09 Issue: Volume:118 Page:35-40
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Locati L.D.,Piovesan A.,Durante C.,Bregni M.,Castagna M.G.,Zovato S.,Giusti M.,Ibrahim T.,Puxeddu E.,Fedele G.,Pellegriti G.,Rinaldi G.,Giuffrida D.,Verderame F.,Bertolini F.,Bergamini C.,Nervo A.,Grani G.,Rizzati S.,Morelli S.,Puliafito I.,Elisei R.

Funder

EISAI

Eisai

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Dal Maso L. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis;Vaccarella;N Engl J Med,2016

2. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5;Dal Maso;Eur J Canc,2017

3. I numeri del cancro 2017.

4. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer;Lorusso;OncoTargets Ther,2016

5. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question;Elisei;J Clin Endocrinol Metab,2010

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of TSHR-CAR NK-92 cells for Differentiated Thyroid Cancer;Molecular and Cellular Endocrinology;2024-08

2. Schilddrüsenkarzinome – Rolle internistischer Systemtherapien;Die Innere Medizin;2024-06-20

3. Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer;Endocrine;2024-05-21

4. Effectiveness and safety of lenvatinib in a series of advanced well-differentiated thyroid carcinomas from a single tertiary cancer center and literature review;Minerva Endocrinology;2024-03

5. Lenvatinib-Loaded Poly(lactic-co-glycolic acid) Nanoparticles with Epidermal Growth Factor Receptor Antibody Conjugation as a Preclinical Approach to Therapeutically Improve Thyroid Cancer with Aggressive Behavior;Biomolecules;2023-11-13